Wang Li, Zhang Yan-Li, Wang Xiu-Fang, Song Zhe, Wang Wei
Department of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2017 Jan;19(1):104-110. doi: 10.7499/j.issn.1008-8830.2017.01.017.
To study the expression and significance of the mammalian target of rapamycin (mTOR)/eukaryote initiating factor 4E binding protein 1(4EBP1)/hypoxia inducible factor-1α (HIF-1α)/vascular endothelial growth factor (VEGF) signaling pathway in asthmatic mice.
Forty SPF level 6-8 week-old female Balb/C mice were randomly divided into control, asthma, budesonide and mTOR inhibitor (rapamycin) intervention groups (n=10 each). The asthmatic mouse model was prepared via OVA induction and challenge test. The intervention groups were administered with rapamycin at the dosage of 3 mg/kg by an intraperitoneal injection or budesonide suspension at the dosage of l mg by aerosol inhalation respectively 30 minutes before the OVA challenge. The control and asthma groups were treated with normal saline instead. The concentrations of HIF-1α and VEGF in bronchoalveolar lavage fluid (BALF) were examined using ELISA 24 hours after the last challenge. The pathological changes of lung tissue were observed by hematoxylin-eosin (HE) staining. The p-mTOR and p-4EBP1 from the lung tissues were detected by immunohistochemistry and Western blot. Pearson analysis was used to study the correlation between p-mTOR, p-4EBP1, HIF-1α, and VEGF expression.
Compared with the control group, inflammatory cell infiltration and secretions in the trachea increased in the asthma group. The levels of HIF-1α and VEGF in BALF and p-mTOR and p-4EBP1 expression in lung tissues also increased (P<0.01). Compared with the asthma group, inflammatory cell infiltration and secretions in the trachea were reduced in the two intervention groups, and the levels of HIF-1α and VEGF in BALF and p-mTOR and p-4EBP1 expression in lung tissues were also reduced (P<0.01). There were no significant differences in the above changes between the two intervention groups and control group (P>0.05). In the asthma group, there was a pairwise positive correlation between lung p-mTOR and p-4EBP1 expression and HIF-1α and VEGF levels in BALF (P<0.05). However, there were no correlations in the above indexes in the intervention groups and control group.
p-mTOR, p-4EBP1, HIF-1α and VEGF together are involved in the pathogenesis of asthma. Rapamycin treatment can block this signaling pathway, suggesting that this pathway can be used as a novel target for asthma treatment.
研究雷帕霉素哺乳动物靶点(mTOR)/真核生物起始因子4E结合蛋白1(4EBP1)/缺氧诱导因子-1α(HIF-1α)/血管内皮生长因子(VEGF)信号通路在哮喘小鼠中的表达及意义。
将40只6-8周龄SPF级雌性Balb/C小鼠随机分为对照组、哮喘组、布地奈德组和mTOR抑制剂(雷帕霉素)干预组(每组n = 10)。通过卵清蛋白(OVA)诱导和激发试验制备哮喘小鼠模型。干预组在OVA激发前30分钟分别腹腔注射3 mg/kg雷帕霉素或雾化吸入1 mg布地奈德混悬液。对照组和哮喘组用生理盐水代替。末次激发后24小时,采用酶联免疫吸附测定(ELISA)检测支气管肺泡灌洗液(BALF)中HIF-1α和VEGF的浓度。苏木精-伊红(HE)染色观察肺组织病理变化。免疫组织化学和蛋白质印迹法检测肺组织中p-mTOR和p-4EBP1。采用Pearson分析研究p-mTOR、p-4EBP1、HIF-1α和VEGF表达之间的相关性。
与对照组相比,哮喘组气管内炎性细胞浸润及分泌物增多。BALF中HIF-1α和VEGF水平以及肺组织中p-mTOR和p-4EBP1表达也增加(P<0.01)。与哮喘组相比,两个干预组气管内炎性细胞浸润及分泌物减少,BALF中HIF-1α和VEGF水平以及肺组织中p-mTOR和p-4EBP1表达也降低(P<0.01)。两个干预组与对照组上述变化无显著差异(P>0.05)。在哮喘组,肺组织p-mTOR和p-4EBP1表达与BALF中HIF-1α和VEGF水平呈两两正相关(P<0.05)。然而,干预组和对照组上述指标无相关性。
p-mTOR、p-4EBP1、HIF-1α和VEGF共同参与哮喘的发病机制。雷帕霉素治疗可阻断该信号通路,提示该通路可作为哮喘治疗的新靶点。